ࡱ> 57234 bjbjT~T~ 66L!$P) 5 <~q!I#|###'\*-.$oX9$3''$3$3##QK(777$3`##7$377u@<#SY4BH`طs~i5i<i<~/r07 11x~/~/~/7^~/~/~/$3$3$3$3i~/~/~/~/~/~/~/~/~/ :  Massachusetts Department of Public Health (MDPH) Division of Epidemiology and Immunization Control of Influenza and Pneumococcal Disease in Long-Term Care Facilities 2010 - 2011  Key Influenza Recommendations Vaccinate all residents against influenza every year. Begin vaccinating as soon as vaccine is available. Ensure that all residents have received a dose of pneumococcal vaccine; 2 doses if the first dose was before their 65th birthday. The Centers for Medicaid and Medicare Services (CMS) require nursing homes to offer all residents flu and pneumococcal vaccines. Vaccinate residents unless contraindicated, the resident or legal representative refuses or there is a vaccine shortage.  HYPERLINK "http://www.cms.hhs.gov/NursingHomeQualityInits/downloads/NHQIVaccinationSupplement.pdf" http://www.cms.hhs.gov/NursingHomeQualityInits/downloads/NHQIVaccinationSupplement.pdf Use only oseltamivir or zanamivir for the treatment and prophylaxis of influenza. Massachusetts Regulation Requires LTC Facilities to offer Flu Vaccine to Employees Regulation [105 CMR 150.002(D)(8)] requires that long-term care facilities (LTCF): Provide every employee with information about the risks and benefits of influenza vaccine; Offer influenza vaccine to every employee no later than December 15. All employees should be vaccinated unless the vaccine is medically contraindicated; vaccination is against the employees religious beliefs; or the employee refuses the vaccine. Arrange for the vaccination of employees hired between December and April 1 who cannot provide proof of current immunization against influenza, < 2 weeks commencing employment. Require employees who do not get vaccinated to sign a statement certifying that he /she received information about the risks and benefits of influenza vaccine. A sample Declination of Influenza Vaccination form is found at  HYPERLINK "http://www.mass.gov/Eeohhs2/docs/dph/quality/hcq_circular_letters/flu_all_attachment_b.pdf" http://www.mass.gov/Eeohhs2/docs/dph/quality/hcq_circular_letters/flu_all_attachment_b.pdf. Maintain in each employees personnel file a certificate of annual influenza vaccination or a signed declination statement. The MDPH Adult Vaccine Documentation Record can be found at  HYPERLINK "http://www.mass.gov/Eeohhs2/docs/dph/cdc/immunization/record_vaccine_admin.pdf" http://www.mass.gov/Eeohhs2/docs/dph/cdc/immunization/record_vaccine_admin.pdf. Maintain a central system to track the vaccination status of every employee. For more information, see the MDPH Circular Letter: DHCQ 06-11-468 at  HYPERLINK "http://www.mass.gov/Eeohhs2/docs/dph/quality/hcq_circular_letters/ltc_facilities_0611468.pdf" www.mass.gov/Eeohhs2/docs/dph/quality/hcq_circular_letters/ltc_facilities_0611468.pdf. Influenza is often introduced into and spread throughout a facility by staff or visitors. Flu vaccine may be less effective in the very elderly and some vaccinated LTC residents may remain susceptible. It is important to reduce their exposure to flu. HCP vaccination reduces mortality in elderly patients. Flu vaccination of health care workers protects the health care workers, their patients, and their families. Flu vaccination is an occupational health and patient safety issue. An updated Employee Immunization Campaign Toolkit is available online at  HYPERLINK "http://www.massmed.org/AM/Template.cfm?Section=Flu" www.massmed.org/AM/Template.cfm?Section=Flu, or by calling 781-419-2749. Where to purchase vaccine: During flu season, go to  HYPERLINK "http://www.preventinfluenza.org/ivats/" http://www.preventinfluenza.org/ivats/ for a list of distributors with flu vaccine to sell. Vaccine may also be available directly from the manufacturers below. Approved Influenza Vaccines for Different Age Groups ManufacturerTrade NameDose/ PresentationThimerosal (mcg Hg/0.5 mL dose)Age Groupsanofi pasteur 800-822-2463  HYPERLINK "https://www.vaccineshoppe.com/" https://www.vaccineshoppe.com/ Fluzone Inactivated New formulation! Fluzone High-Dose 0.25 mL prefilled syringe 0.5 mL prefilled syringe 0.5 mL vial 5.0 mL multidose vial 0.5 mL prefilled syringe 0 0 0 25 06 35 mos > 36 mos > 36 mos > 6 mos > 65 yrsNovartis 800-244-7668  HYPERLINK "https://www.novartisvaccinesdirect.com/index" https://www.novartisvaccinesdirect.com/index Fluvirin Inactivated New vaccine! Agriflu, Inactivated0.5 mL prefilled syringe 5.0 mL multidose vial 0.5 mL prefilled syringe< 1.0 25 0> 4 yrs > 4 yrs > 18 yrs GlaxoSmithKline 866-475-8222  HYPERLINK "https://www.gskvaccinesdirect.com/gsk/en/US/adirect/gsk" https://www.gskvaccinesdirect.com/gsk/en/US/adirect/gsk Fluarix, Inactivated FluLuval"!, Inactivated0.5 mL prefilled syringe 5.0 mL multidose vial0 25> 3 yrs > 18 yrsCSL Biotherapies 888-435-8633Afluria, Inactivated0.5 mL prefilled syringe 0 > 9 yrsMedImmune 877-358-6478FluMist, Live attenuated intranasal0.2 mL sprayer02 49 yrs State-supplied Tetanus/diphtheria (Td) Vaccine: DPH provides Td for all Massachusetts residents for whom it is recommended, including residents of LTC facilities. To order state-supplied Td, contact the DPH Vaccine Unit at 617-983-6828. Tdap (tetanus, diphtheria and acellular pertussis vaccine) should replace a single dose of Td for adults ages 19 64 years who have not received a dose of Tdap previously Influenza Prevention and Control Measures Strategies for the prevention and control of influenza in long-term care facilities include: Annual influenza vaccination of all residents and health-care personnel Standard and droplet precautions with suspect or confirmed influenza cases Active surveillance and influenza testing for new illness cases Restriction of ill visitors and personnel Administration of antiviral medications for prophylaxis and treatment Handwashing and respiratory hygiene/cough etiquette programs Vaccination Vaccination of Residents: Use a systematic approach to vaccination, with checklists, to increase immunization levels: Vaccinate residents against flu when vaccine is available. Vaccinate residents admitted from September through March on admission. Ensure that written policies include annual flu vaccination for residents and staff, and pneumococcal polysaccharide vaccine (PPV23) and Td vaccination for residents. Include Vaccine Information Statements (VIS) for PPV23, Td and flu vaccines in the admission packet. Obtain consent for vaccination from the resident or a family member on admission. Implement standing orders for administration of flu, PPV23 and Td vaccines. These vaccines are safe and effective when administered simultaneously in separate syringes at different anatomical sites. Chart audits should ensure that there is documentation in every chart that the resident has been offered PPV23 and Td vaccines and annual influenza vaccine. Pneumococcal polysaccharide vaccine (PPV23): Pneumococcal pneumonia is the most common nursing home-acquired pneumonia. The case fatality rate is 5-7% and may be much higher in elderly persons. Pneumonia is the primary reason LTC residents require hospitalization. Increasing antimicrobial resistance complicates treatment of pneumococcal disease. PPV23 protects against pneumococcal meningitis and bacteremic pneumococcal pneumonia, a complication of influenza. Administer PPV23 to all unvaccinated residents > 2 years of age on admission. Administer a second dose to previously vaccinated residents who are > 65 years of age if it has been > 5 years since their first dose and they were < 65 years of age when they received the first dose. Local reactions at the injection site may follow both first PPV23 vaccination and revaccination. These reactions are self-limiting and are not a contraindication to vaccination. Td vaccine: More than 50% of tetanus cases in the U.S. are people age > 60 years; one fourth of these are associated with chronic wounds, such as decubiti. Administer Td on admission to all residents without immunization records, and to those for whom it has been > 10 years since their last dose. Consider residents with uncertain immunization histories NOT immunized and vaccinate accordingly. The benefits of vaccination far outweigh any concerns about revaccination. Medicare Reimbursement for Administration of Influenza and Pneumococcal Vaccines: Medicare reimburses both for the cost of influenza and pneumococcal vaccines and for administration of the vaccines. Medicare reimbursement for administration of flu and pneumococcal vaccines for 2009-2010 was $25.21/dose in metro-Boston and $22.41/dose in the rest of the state. For more information, see  HYPERLINK "http://www.cms.hhs.gov/AdultImmunizations/" www.cms.hhs.gov/AdultImmunizations/ Vaccination of Family Members and Visitors: Inform family members and other visitors about their role in the transmission of flu to patients and encourage them to get vaccinated. To find flu vaccine, they can call their health care provider or local board of health, visit the MassPRO website at  HYPERLINK "http://flu.masspro.org" http://flu.masspro.org for a list of flu vaccination clinics by town, or call MDPH at 1-866-627-7968. Surveillance, Testing and Reporting Surveillance: Conduct surveillance for respiratory illness and use influenza testing to identify outbreaks so infection control measures can be promptly initiated in all settings, including inpatient and outpatient settings. Call MDPH at 617-983-6800 for guidance and assistance with surveillance and control measures. Influenza testing: Diagnostic testing for influenza can aid clinical judgment and guide treatment decisions and control measures. Diagnostic tests for influenza performed at the Hinton State Laboratory Institute (SLI) include viral culture and influenza RNA detection by polymerase chain reaction (PCR). Point of care rapid antigen testing capable of detecting influenza A and B virus infections is not routinely performed at the SLI but is widely available at hospitals, private providers and other healthcare settings. Rapid influenza diagnostic tests have limited sensitivity and false negative results are common. False positive tests can also occur and are more likely when flu is rare in the community. When laboratory confirmation is desired, testing by RT-PCR and/or viral culture is recommended. PCR and viral culture testing also provide essential information on circulating influenza subtypes and strains. For information on influenza specimen collection and transportation, or to speak with an immunization epidemiologist, call MDPH at 617-983-6800. For specimen collection kits, call the kit room at the SLI at 617-983-6640. Reporting: Per 105 CMR 300, influenza-associated pediatric deaths and illness due to novel influenza A viruses and should be reported immediately to the local board of health or to the MDPH at 617-983-6800 or 888-658-2850. Providers and facilities must also report all outbreaks of influenza-like illness (ILI) to their local board of health and to the Division of Healthcare Quality at 800-462-5540 x8150 , and all outbreaks should be reported to the MDPH within 24 hours of outbreak recognition. Providers should notify MDPH immediately of all ICU admissions and deaths in pregnant women with any type of influenza. All influenza cases confirmed with diagnostic testing are reportable to MDPH. For specific information about reporting, see the MDPH Reportable Diseases, Surveillance and Isolation & Quarantine Requirements website at  HYPERLINK "http://www.mass.gov/Eeohhs2/docs/dph/cdc/reporting/rdiq_reg_summary.rtf" http://www.mass.gov/Eeohhs2/docs/dph/cdc/reporting/rdiq_reg_summary.rtf. Additional information on the prevention and control of influenza can be found in the influenza chapter of the MDPH Guide to Surveillance, Reporting and Control, at  HYPERLINK "http://www.mass.gov/Eeohhs2/docs/dph/disease_reporting/guide/influenza.rtf" http://www.mass.gov/Eeohhs2/docs/dph/disease_reporting/guide/influenza.rtf. Infection Control Promptly implement the outbreak control measures described below and contact MDPH at 617-983-6800 and the Division of Healthcare Quality at 800-462-5540 x8150 in the event of any one of the following: Influenza is confirmed by laboratory testing in at least one resident More than one resident in the facility or an area of the facility (e.g., separate unit) develops influenza-like illness (ILI) during a 1-week period. ILI is defined as fever > 100o F with cough and/or sore throat, in the absence of a known cause. MDPH epidemiologists can facilitate testing and provide control recommendations in the event of an outbreak. To prevent the transmission of all respiratory infections, including flu, implement the infection control measures listed below at the first point of contact with a potentially infected person. Incorporate these measures into infection control practices as one component of standard precautions. Find tools to help promote and implement these recommendations at  HYPERLINK "http://www.cdc.gov/flu/professionals/infectioncontrol" www.cdc.gov/flu/professionals/infectioncontrol. Active surveillance and testing for new illness and cases: Educate staff about the signs and symptoms of influenza-like illness. The ILI line list found on the last page of this document can be used to collect and manage relevant information about ill residents and staff. Respiratory hygiene/cough etiquette: Post visual alerts in appropriate languages at the entrance to outpatient facilities (e.g., emergency departments, physician offices) instructing patients and people who accompany them (e.g., family, friends) to inform health care personnel of symptoms of a respiratory infection when they first register for care and to practice respiratory hygiene/cough etiquette. Posters, brochures and fact sheets promoting cough etiquette and handwashing in multiple languages are available from MDPH by calling 617-983-6800 or they can be downloaded from  HYPERLINK "http://www.mass.gov/handwashing" www.mass.gov/handwashing. Use standard precautions ( HYPERLINK "http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html" http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html) with all patients and implement droplet precautions ( HYPERLINK "http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html" http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html) when caring for patients with suspected or confirmed influenza. For more information and up-to-date recommendations for influenza infection control, visit the CDC website at:  HYPERLINK "http://www.cdc.gov/flu/professionals/infectioncontrol" www.cdc.gov/flu/professionals/infectioncontrol. Antiviral drugs are an adjunct to, not a substitute for, vaccination for preventing and controlling influenza. The neuraminidase inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza) are currently recommended for use against circulating influenza viruses. The adamantanes (amantadine and rimantadine) are not recommended because of high levels of resistance to these drugs among recently circulating influenza A (H3) and 2009 H1N1 pandemic viruses. Clinical judgment is an important factor in treatment decisions for patients presenting with influenza-like illness. Prompt empiric antiviral treatment with influenza antiviral medications is recommended while results of definitive diagnostic tests are pending, or if diagnostic testing is not possible, for patients with clinically suspected influenza illness who have: Illness requiring hospitalization, Progressive, severe, or complicated illness, regardless of previous health status, and/or Patients at increased risk for severe disease (see page 3). Do not delay antiviral treatment, when clinically indicated, pending definitive laboratory confirmation of influenza. Influenza antiviral medications are most effective when initiated within 2 days of illness, but these medications may also provide benefits for severely ill patients when initiated even after 2 days. Point of care rapid tests capable of detecting influenza A and B virus infections are available, but health care providers and public health personnel should be aware that rapid influenza diagnostic tests have limited sensitivity and false negative results are common. Thus, negative results from rapid influenza diagnostic test should not be used to guide decisions regarding treating patients with influenza antiviral medications. In addition, false positive tests can occur and are more likely when influenza is rare in the community. When laboratory confirmation is desired, testing by RT-PCR and/or viral culture is recommended. Guidance on use of antivirals may change depending upon resistance data. Consult CDCs latest recommendations on antiviral use at  HYPERLINK "http://www.cdc.gov/flu/professionals/" www.cdc.gov/flu/professionals/. ACIP recommendations are not yet available. When they are, they will be available at  HYPERLINK "http://www.cdc.gov/vaccines/recs/acip/default.htm" www.cdc.gov/vaccines/recs/acip/default.htm Clinicians should be alert to changes in antiviral recommendations that might occur as additional antiviral resistance data becomes available during the 2010-2011 season. Additional Information CDC. Prevention and control of influenza with vaccines: recommendation of the ACIP, 2010. MMWR Early Release 2010;59 July 29, 2010:1-62.  HYPERLINK "http://www.cdc.gov/mmwr/pdf/rr/rr59e0729.pdf" http://www.cdc.gov/mmwr/pdf/rr/rr59e0729.pdf CDC. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory (HICPAC) and the Advisory Committee on Immunization Practices (ACIP) 2006:55(No. RR-2).  HYPERLINK "http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htm" http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htm. CDC. Prevention of pneumococcal disease: recommendations of the ACIP. MMWR 1997;46 (No. RR-8).  HYPERLINK "http://www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm" http://www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm Package inserts for all 2010-2011 approved influenza vaccine formulations:  HYPERLINK "http://www.immunize.org/fda/pa_influenza.asp" http://www.immunize.org/fda/pa_influenza.asp Vaccine Information Statements (VISs) for all vaccines in many languages:  HYPERLINK "http://www.immunize.org/vis" www.immunize.org/vis. Visit the MDPH web site  HYPERLINK "http://www.mass.gov/dph/flu" www.mass.gov/dph/flu. Hard copies and technical consultation are available by calling MDPH at 617-983-6800 or 888-658-2850. NamePatient (P) or Staff (S)AgeWing/ UnitFlu Vax?Pneumo Vax?Date of OnsetSymptoms (check box)CXR? Findings?Hospitalized?Died?Flu Dx test and resultOther tests and resultsAnti- viral?Fever (temp)CoughSore throatURIMuscle AchesWeaknessVomitingDiarrhea1 23456789101112131415TOTALINFLUENZA-LIKE ILLNESS (ILI) Facility Name:___________________________________ LINE LIST Date: __________     PAGE 6 PAGE 1  FILENAME \* MERGEFORMAT Control of ILI in LTCFs 2010.doc -4^_`   ûñvj[O[@h,>|h5:CJ\aJhc`5:CJ\aJh,>|hBD 5:CJ\aJh. hBD :\aJh. hBD :>*\aJ'jhFq:>*U\aJmHnHu#jh?h :UmHnHuh?h : hc`: h :h h :h h :h?h :CJh?h 5:h?hm|5:CJh?h 5:CJh!y5:CJ5_`D *  XD<gdvi]gd  & F hhd7$8$H$^hgdSF 7$8$H$gdBD d1$$<1$a$$a$gd $1$a$($ A`0`p @ 0@1$a$ A B C D l m * - . H \ ] ( ) * ̮̝̽̑nWnFn!h,>|hf%0J5:CJ\aJ,jh,>|hf%5:CJU\aJ&jh,>|hf%5:CJU\aJh,>|hf%5:CJ\aJhf%5:CJ\aJ h,>|hBD 5:CJH*\aJh,>|h05:CJ\aJh,>|h5:CJ\aJh,>|hBD 5:CJ\aJhFq5:CJ\aJhFy5:CJ\aJh.O5:CJ\aJ ) * + 5 6 K L M U { } ~   I K t u ʾʲth\\\Nth,>|hg|!5:CJaJh,>|hg|!5:CJh,>|h+&5:CJh,>|h5:CJaJh,>|hvi5:CJh,>|h5:CJh,>|hBD 5:CJh,>|hY5:CJh,>|hBD 5>*CJh,>|h 5>*CJh,>|hY5>*CJhFy5>*CJ h,>|hBD 5:>*CJ\aJh,>|hBD 5:CJ\aJ 0(~o7$8$H$^gdSFgdvi1$z$d%d&d'dNOPQ]^za$gdFq x^gdSFxgd# & F 8Pgd5# & F hhP^hgd5 & FPgd5 & F%Pgd5 bcf#$&ǴǴqbSD3 h,>|hvCJOJQJ^JaJh,>|hvCJOJQJaJh,>|hLCJOJQJaJh,>|h+&CJOJQJaJh,>|hviCJOJQJaJh,>|hCJOJQJaJ h,>|hviCJOJQJ^JaJ'h,>|hL>*CJOJPJQJ^JaJ$h,>|hCJOJPJQJ^JaJ$h,>|hisCJOJPJQJ^JaJ$h,>|h:lCJOJPJQJ^JaJ$h,>|hLCJOJPJQJ^JaJ&-Vcd()+,-/0Ǵ~gVC0$h,>|hisCJOJPJQJ^JaJ$h,>|hYCJOJPJQJ^JaJ h,>|hYCJOJQJ^JaJ-HhFh,>|hvCJOJQJ^JaJ hhSF0JCJOJQJ^J+jhhSFCJOJQJU^JhhSFCJOJQJ^J%jhhSFCJOJQJU^J h,>|hvCJOJQJ^JaJ-HhFh,>|hvCJOJQJ^JaJ h,>|h CJOJQJ^JaJFGH -.ijĈxeWC1W#jh,>|hm|5:CJUaJ&h,>|hm|5:B*CJ\aJphh,>|hm|5:CJaJ$h,>|hisCJOJPJQJ^JaJhSFCJOJPJQJ^JaJ$hSFhSF0JCJOJQJ^JaJ/jhSFhSFCJOJQJU^JaJ hSFhSFCJOJQJ^JaJ)jhSFhSFCJOJQJU^JaJ'h,>|hd50J(5CJOJQJ^JaJ$h,>|hd5CJOJPJQJ^JaJCKNOR'(+aغ|||s||j^Rh,>|h5:CJh,>|hL5:CJh,>|hF kCJh,>|hFqCJ hFqCJh,>|hYCJh,>|h0CJh,>|h+CCJh,>|hLCJ hFyCJh,>|h5:CJaJh,>|hm|5:CJaJh,>|hm|0J5:CJaJ#jh,>|hm|5:CJUaJ)jch,>|hm|5:CJUaJaq*BC߱seYNA7h.OCJmH sH h0?h.OCJmH sH hh.OmH sH hh.O5mH sH h+{h.O5CJmH sH h,>|h5:CJaJh,>|h0J5:CJ(j>h,>|h5:>*CJUh,>|h5:>*CJ"jh,>|h5:>*CJUh,>|h56:CJ]h,>|hvi5:CJ]h,>|h5:CJh.O5:CJh,>|hV+5:CJ:<=>detCMbcmn窘xn`P`nI hhc`h6`hc`:CJaJmH sH h6`hc`:CJmH sH h6`hc`:CJ#hc`hc`:OJQJaJmH sH hc`hc`:OJQJ\"hrhh.O:CJOJQJ\aJh0?h.OCJmH sH h*CJaJmH sH "h6`hc`5:CJaJmH sH "h6`hc`5:CJaJmH PsH P"h6`hc`5:CJaJmHsHh6`hb5:CJaJh6`hc`5:CJaJ)h6`hc`5:B*CJ\]aJphh6`hc`0J5:CJaJ)jY h6`hc`5:CJUaJ#jh6`hc`5:CJUaJh6`hc`5:CJaJ4MYottt ZH<$1$If]Hgd6` ZHx$1$If]Hgd6` Z<$1$If]gd6` Z$1$If]gd6` Zx$1$If]gd6`Z$If^Zgd6` H($1$If]Hgd6` oxxxd$ Z$1$Ifa$gd6`$ Z<$1$Ifa$gd6`$ Zx$1$Ifa$gd6`$ Z#$1$If]#a$gd6`$ Z#<$1$If]#a$gd6`$ Z#x$1$If]#a$gd6` ZH<$1$If]Hgd6` HIKUamͿzeSDDDDh6`hc`5:>*CJaJ"h6`hc`5:CJaJmHsH)h6`hc`5:B*CJ\]aJphh6`hc`5:CJaJh6`hc`0J5:CJaJ)j% h6`hc`5:CJUaJ#jh6`hc`5:CJUaJh6`hc`5:CJaJh6`hc`5CJmH sH %h6`hc`5:>*CJaJmH sH "h6`hc`5:CJaJmH sH J3 H($1$If]Hgd6` Hx($1$If]Hgd6`kdJ $$Ifl+r0:l*#( p2  t0*44 layt6`KUannV$ Z#x$1$If]#a$gd6` ZHh$1$If]Hgd6` ZH<$1$If]Hgd6` ZHx$1$If]Hgd6` Z$1$If]gd6` Z$1$If]gd6` Zx$1$If]gd6` H($1$If]Hgd6` $ Z&h$1$Ifa$gd6`$ Z&<$1$Ifa$gd6`$ Z&x$1$Ifa$gd6`$ Z#h$1$If]#a$gd6`$ Z#<$1$If]#a$gd6`J5" H$1$If]Hgd6` Hx$1$If]Hgd6`kdN $$IflNr0:l*#( p2  t0*44 layt6` "6N^d|հ璢gR:.jh6`hc`5:CJUaJmHnHu(h6`hc`5:>*CJaJmHnHu1jh6`hc`5:>*CJUaJmHnHu"h6`hc`5:CJaJmHsHh6`hc`5:B*CJphh6`hc`5:CJaJh6`hc`0J5:CJaJ)j)h6`hc`5:CJUaJ#jh6`hc`5:CJUaJh6`hc`5:CJaJh6`hc`5CJ"N||dL$ ZHx$1$If]Ha$gd6`$ Z#h$1$If]#a$gd6`$ Z#x$1$If]#a$gd6` ZHh$1$If]Hgd6` ZHx$1$If]Hgd6` Z<$1$If]gd6` Zx$1$If]gd6` Hx$1$If]Hgd6`:XYZ_`ax&()+^`Ƴơ؇}sl}bYSYMYM hc`CJ h CJh,>|h+CCJh,>|h{L5CJ h 5CJh,>|hg|!5CJh,>|h5CJhc`hc`5CJaJh6`hc`5:CJaJ"h6`hKa5:CJaJmHsH%h6`hc`5:>*CJaJmHsH"h6`hc`5:CJaJmHsHh6`hc`5CJh6`hc`5:CJaJh6`hc`5:>*CJaJ2 Hx$1$If]Hgd6`kd~$$Iflr0:l*#( p2  t0*44 layt6`$ ZHh$1$If]Ha$gd6`$:SX`$ ZHx$1$If]Ha$gd6`$ Z#x$1$If]#a$gd6` ZHx$1$If]Hgd6` Zx$1$If]gd6` H$1$If]Hgd6``akxJ5" H$1$If]Hgd6` Hx$1$If]Hgd6`kdY$$Iflr0:l*#( p2  t0*44 layt6`x$ ZHh$1$If]Ha$gd6`$ Z#h$1$If]#a$gd6` ZHh$1$If]Hgd6` ZxP$1$If]gd6`XYL?9391$gdg|!1$gdb 7$8$H$]gdc`kd4$$Iflr0:l*#( p2  t0*44 layt6``WXY78?@KZ& ' 6 c d o p ³wwoeXNh,sh >*CJh,sh 5>*CJ\h,s5>*CJ\hf%CJaJh,>|hN? CJaJhKaCJaJh,>|h0CJaJh,>|h 5>*CJ\hh,>|h5>*CJ\hh,>|h5>*CJ\hh,>|h>*CJ\hh!FhrhCJmHnHuhrhCJmHnHuh,>|hCCJ h CJh,>|h+CCJ*u& c d p m!""#5$ &')x1$gdf% x1$gdf% & F h8h(1$^hgdrh & F hh(1$^hgdrh  xgd,sgdSF  & F$<gdFy<gd0p !!! !E!N!m!!!!!!!!!!!!"""""G"~qeXh,>|h 5:CJ\h,>|hfn5:CJh,>|hfn5:CJ\h,>|hp5:CJh,>|h 5:CJh,>|hl5:CJh 5:CJhf%5:CJh,>|h5:CJh,>|h. 5:CJh,>|h{LCJh,>|h. CJh,>|hgCJ\h,>|hg5CJ\h,>|h 5CJ\G"L"U"Y"b"d"|"""""""""""##### ###4$5$¶}¶qhqh\OCOh,>|hg5:CJh,>|hg5:CJ\h,>|hf%5:CJhf%5:CJh,>|h,-5:CJh,>|h :CJh,>|hfn5:CJh,>|hfn5:CJ\hbhb5:CJ\hb5:CJh,>|hF k5:CJh,>|h 5:CJh,>|h. 5:CJ\h,>|h,-5:CJ\h,>|h 5:CJ\h 5:CJ\5$`$c$d$p$y$%%&8&9&E&V&X&c&k&u&&&&&&&&&&&&&!'"'H'R'^'d'l'''''''ӻӢӻӻljӻ}ӻqh,>|hL5:CJh,>|h5:CJh,>|hH5:CJh,>|hGL5:>*CJh,>|h+C5:CJh,>|h 5:>*CJh,>|h 5:CJh,>|hGL5:CJh,>|h,-5:CJh,>|hg5:CJh,>|h,-:CJh,>|h :CJ)'' (((((%(*(((((()V)c)d)))*c*y**ƺ~wmaUB$h.Oh.O5:CJ\mHnHuh.OhIJ5:CJh.OhR5:CJh.OhR:CJ h_:CJh_hH5CJ h_5CJh_hF k5CJh_h_5CJh,>|h :CJh,>|h 5:>*CJh,>|h 5:CJh,>|hGL5:CJh,>|h,-5:>*CJh,>|hH5:CJh,>|h,-5:CJh,s5:CJ)))+[--.=3)7y8z88yqix1$gdrh1$gdSFgdSFxgdSF& 20Tp 4Pl%H1$@&]HgdSF xgdq gdq hh^hgdb0$d%d&d'dNOPQ]^gdb **7+8+p+q+r++++++++++,,),ƱԡԖ~pbTH<3<hFy5:CJh.Oh 5:CJh.OhJ5:CJh.OhJ5:CJaJh.Oh+C5:CJaJh.OhF k5:CJaJh.OhF k:CJaJh.Oh :CJaJh.O5:CJaJh.Oh.O0J5:CJaJ)j h.Oh.O5:CJUaJh.Oh.O5:CJaJ#jh.Oh.O5:CJUaJh.Oh.O5:CJh.Oh.O5:CJ\),7,;,I,K,L,X,_,a,e,,,,,,,,,, --)-6-7-<-?-M-N-Z-[---褷~rrfR&jhKahSF5U\mHnHuhKahSF:>*CJh.OhC5:CJh.Oh5:CJh.OhJ5:CJh.Oh 0J5:CJ%jh.Oh 5:CJUjh.Oh 5:CJUh.OhF k5:CJh.Oh{L5:CJhFy5:CJh.Oh 5:CJh.Oh+C5:CJ----.....0P0001121J1O1n1q111"222<3=3I3(474444445,6οιιΛ||p|bhKahSF5:CJaJh^FhSF5:CJhSF5:CJhKahSF5:CJhKahSF:CJhKahSFCJaJhSFCJaJhKahSFCJaJ hSFCJhKahSFB*CJaJphhKahSFCJhKahSFCJ\hKahSF5CJhSF hKahSFhKahSF5\#,616z666666%7&7(7)77777'8ĪĐfWFW2W&jhKahSF5:CJU\aJ hKahSF56:CJ\aJhKahSF5:CJ\aJ3h^FhSF0J(:B*CJOJQJ\^JaJphhKahSF0J5:CJaJ2jhKahSF5:B*CJUaJph2jhKahSF0J(5:CJOJQJU\aJ)hKahSF0J(5:CJOJQJ\aJ,hKahSF0J(56:CJOJQJ\aJhKahSF56:CJaJ'8(8)8s8t8y8z88888+93:4:L:M:Q:S::;;յzpfZfNfD8h;]hSF5CJ\h;]hSF5CJh,>|hSFCJH*\h,>|hSF>*CJ\h,>|hSFCJ\h^FhSFCJ\h;]hSFCJh,>|hSFCJ hSFCJhKahSF:CJhKahSF:>*CJhKahSF5:>*CJhKahSF5:CJ\aJ!hKahSF0J5:CJ\aJ&jhKahSF5:CJU\aJ,jhKahSF5:CJU\aJ8V994::;<=@=B#CDaFzzxgdP1$gdSF1$gdSF  !xgdrhxgdrh-$ $d%d&d'dNOPQa$gdrh & F hB<x^`Bgdrh & F<`gdrhxgdSF ;;";%;H;K;M;W;;;-<3<l<o<p<<<<<<<!=h===>> >K>׾׾׾׾{obXLhKahSF5:CJhKahSF:CJhKahSF5:CJ\hKahSF:CJ\hKahSF5CJ\hKahSF0JCJjWhKahSFCJUjhKahSFCJU hSFCJhKahSFCJhSFB*CJaJphhKahSF0J CJaJhKahSFB*CJaJph1jhKahSFB*CJUaJmHnHphuK>L>>>????B@C@p@q@r@@@@@@@@@@@5A6A8AJAYAkAmAnAAAAAABBBέ롗έqέ%jhKahSF5:CJU%j}hKahSF5:CJUhKahSF:CJhKahSF:CJ\hKahSF0J5:CJ%jhKahSF5:CJUjhKahSF5:CJUhKahSF5:CJ\hKahSF5:CJhSF5:CJ&BBB C!C#C2CCCCDDD^FG*GYGGXH\HHJJ\K]KK¶u__Ojhh5:CJU*hh5:B*CJ\^JaJph!h5:B*CJ^JaJphhh5:CJ^JaJ'hh5:B*CJ^JaJphhh5:CJhh:CJ\hKahSF5:CJhKahSF0J5:CJjhKahSF5:CJU%jhKahSF5:CJUaFFFG\HJzL%M=M3NOdPQQr  !h<gdrh #<1$]#gdrh<gdrh h<gdrh <7$8$H$gdrhgdSF-$xx$d%d&d'dNOPQa$gd xx1$gdxgd & F- (^gd KKKKK L LKLLLMLwLxLzL$M%M=MMMMMNNN¯¦wcLc,jh_hSF5:CJU\aJ&jh_hSF5:CJU\aJhSF5:CJ\aJh_hSF5:CJ\aJh*hSF5\hhCJ\hhCJ%jhh5:CJUhh5:CJhh0J5:CJjhh5:CJU%jhh5:CJUN0N1N3NNOOOO OLOMONOOOOOO˿{k{XkFk{=0h*hSFCJmH PsH Ph*hSFCJ"h*hSF0J5:CJmHsH%j%!h*hSF5:CJUjh*hSF5:CJUh*hSF5:CJmHsH"h*hSF5:CJaJmHsH%h*hSF5:CJ\aJmHsHh*hSF5:CJ\aJh*hSF5:CJh_hSF5:CJ\aJ&jh_hSF5:CJU\aJ!h_hSF0J5:CJ\aJOO*P+P,PaPbPdPPPPPPQQQeQfQQQ巣{mYJ3,jx$h*hSF5:>*CJUaJh*hSF5:>*CJaJ&jh*hSF5:>*CJUaJh*hSF5:CJaJ!h_hSF0J5:CJ\aJ,jO#h_hSF5:CJU\aJ&jh_hSF5:CJU\aJh_hSF5:CJ\aJh*hSF0JCJmH PsH Pjr"h*hSFCJUh*hSFCJmH PsH Pjh*hSFCJUQQQQQQQQQQQRRmRnRoRpR4S=SSSSSSSSSSSS T T!T#T9T;TQTSTiTlTTTTTοέΘܭΑvnvnnnnnnnnnnnnhh :hh CJhh :CJhh \ h*h#)jO%h*hSF5:CJUaJ#jh*hSF5:CJUaJh*hSF5:CJ\aJh*hSF5:CJaJh*hSF0J5:CJaJ&jh*hSF5:>*CJUaJ+QmRnRoRpRuRRRRRRRRRRRRRRRRRS'S$$ &P#$/Ifa$$$ &P#$/Ifa$  h1$gd# h<gdrh'S-S4S5S6S7S8S9S:S;ST?T@TATBTCTDTETFT$$ &P#$/Ifa$FfKW $ &P#$/IfFTGTHTITJTKTLTMTNTOTPTQTSTTTUTVTWTXTYTZT[T\T]T^T_T`T$$ &P#$/Ifa$FfE] $ &P#$/If`TaTbTcTdTeTfTgThTiTlTmTnToTpTqTrTsTtTuTvTwTxTyTzT{T$$ &P#$/Ifa$Ff?c $ &P#$/If{T|T}T~TTTTTTTTTTTTTTTTTTTTTTT$$ &P#$/Ifa$Ff9i $ &P#$/IfTTTTTTTTTTTTTTTTTTTTTTTTTT$$ &P#$/Ifa$Ff3o $ &P#$/IfTTTTTTTTTTTTTTTTTTTTTTTTTT$$ &P#$/Ifa$Ff-u $ &P#$/IfTTTTTTTTUUhttps://www.vaccineshoppe.com/$$If!vh5 5p52 55#v #vp#v2 #v#v:V l+ t0*5 5p52 55ayt6`)DyK -https://www.novartisvaccinesdirect.com/indexyK Zhttps://www.novartisvaccinesdirect.com/index$$If!vh5 5p52 55#v #vp#v2 #v#v:V lN t0*5 5p52 55ayt6`UDyK 8https://www.gskvaccinesdirect.com/gsk/en/US/adirect/gskyK phttps://www.gskvaccinesdirect.com/gsk/en/US/adirect/gsk$$If!vh5 5p52 55#v #vp#v2 #v#v:V l t0*5 5p52 55ayt6`$$If!vh5 5p52 55#v #vp#v2 #v#v:V l t0*5 5p52 55ayt6`$$If!vh5 5p52 55#v #vp#v2 #v#v:V l t0*5 5p52 55ayt6`DyK $www.cms.hhs.gov/AdultImmunizations/yK Vhttp://www.cms.hhs.gov/AdultImmunizations/DyK http://flu.masspro.orgyK 0http://flu.masspro.org/DyK Hhttp://www.mass.gov/Eeohhs2/docs/dph/cdc/reporting/rdiq_reg_summary.rtfyK http://www.mass.gov/Eeohhs2/docs/dph/cdc/reporting/rdiq_reg_summary.rtfyX;H,]ą'cDyK Khttp://www.mass.gov/Eeohhs2/docs/dph/disease_reporting/guide/influenza.rtfyK http://www.mass.gov/Eeohhs2/docs/dph/disease_reporting/guide/influenza.rtfyX;H,]ą'c?DyK /www.cdc.gov/flu/professionals/infectioncontrolyK lhttp://www.cdc.gov/flu/professionals/infectioncontrolDyK www.mass.gov/handwashingyK @http://www.mass.gov/handwashingDyK ?http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.htmlyK http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.htmlyX;H,]ą'cDyK ?http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.htmlyK http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.htmlyX;H,]ą'c?DyK /www.cdc.gov/flu/professionals/infectioncontrolyK lhttp://www.cdc.gov/flu/professionals/infectioncontrolDyK www.cdc.gov/flu/professionals/yK Lhttp://www.cdc.gov/flu/professionals//DyK +www.cdc.gov/vaccines/recs/acip/default.htmyK dhttp://www.cdc.gov/vaccines/recs/acip/default.htm)DyK -http://www.cdc.gov/mmwr/pdf/rr/rr59e0729.pdfyK Zhttp://www.cdc.gov/mmwr/pdf/rr/rr59e0729.pdfMDyK 6http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htmyK lhttp://www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htmDyK yK lhttp://www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm)DyK -http://www.immunize.org/fda/pa_influenza.aspyK Zhttp://www.immunize.org/fda/pa_influenza.aspDyK www.immunize.org/visyK 8http://www.immunize.org/visDyK www.mass.gov/dph/fluyK 8http://www.mass.gov/dph/flu$$If!vh555?5I5555i5 5 R5 5 5 25 (5#v#v#v?#vI#v#v#v#vi#v #v R#v #v 2#v (#v:V l4= 6P 0Z:)v +++++++++ + + + + +,, 555?5I5555i5 5 R5 5 25 (54f4kd&&$$Ifl4=NjC 8N((z,.0379?IiR2( 6P 0Z:<<<<4 laf4Q$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4` 6P 0Z:)v++++++++++++++,555?5I5555i555R5525(54f4kd"+$$Ifl4`jC 8N) "p$K&((z,.0379  ? I    i         R   2 (  6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kdh1$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kdb7$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kd\=$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kdVC$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kdPI$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kdJO$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kdDU$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kd>[$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kd8a$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kd2g$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kd,m$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kd&s$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kd y$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(54f4kd$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4/$$If!vh555?5I5555i5 5 5 5 5 5 555R55525(5#v#v#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 6P 0Z:,555?5I5555i555R5525(5/ / / 4f4kd$$Ifl4jC 8N) "p$K&((z,.0379?IiR2( 6P 0Z:XXXX4 laf4$$If!vh5p5?5I5555i55 5 5 5 5 5 55R55525(5#vp#v?#vI#v#v#v#vi#v#v#vR#v#v2#v(#v:V l4 ( 6P 0Z:,5p5?5I5555i555R5525(54f4pkd8$$Ifl4C 8N) "p$K&((z,.0379p?IiR2( ( 6P 0Z:TTTT4 laf4p^, 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH B`B Normal5:CJ_HmH sH tH <@<  Heading 1$@&5CJ$<@<  Heading 2 $1$@&:  Heading 3{$$ _`p @ 0@P ` !p#$x<1$@&a$:LL  Heading 4$$P1$@&a$ 56:RR  Heading 5!$$`1$@&^``a$:R@R  Heading 6!$$1$@&]^a$:B@B  Heading 7$$1$@&a$CJDA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List <&< Footnote Reference4 @4 Footer  !44 Header  !.)@!. Page Number8B@28 Body Text1$5:NTBN Block Text<1$]^5:RC@RR Body Text Indentx1$^5:Rb Body Text Indent 2w _`p @ 0@P ` !p#$<1$^5:@P@r@ Body Text 21$ 5:CJ0>0 Title$a$:@Y@  Document Map-D OJQJ0U@0 Hyperlink>*B*BQB Body Text 3 $xa$5:NJN Subtitle$00x]0`0a$5CJVSV Body Text Indent 3C<1$^C5:FVF FollowedHyperlink >*B* ph^/^ Default 7$8$H$)B*CJOJQJ_HaJmH phsH tH 6W`6 StrongB*CJaJph8"@8 Caption!:CJ \aJH"H A Balloon Text"CJOJQJ^JaJe@2 BD HTML Preformatted7# 2( Px 4 #\'*.25@95:CJOJPJQJ^Jf^Bf ? Normal (Web)$dd[$\$#5:B*OJPJQJ^JaJphjSj ? Table Grid7:V%0%BaB\vDLazorikCJOJQJ^JaJphFZrF { Plain Text'5:CJOJQJ^JPOP d5 maintitle1#5CJOJQJ\^JaJo(phB'B c`Comment ReferenceCJaJ>> c` Comment Text* 5:CJDjD qComment Subject+ 5:\PK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]  M #nIM K pp}}} &an`p G"5$'*),-,6'8;K>BKNOQTUw+-.0123458;@BHJKLMOPQRSUVWYZ[\kps mo`x)8aFQ'SSSSSST,TFT`T{TTTTTUU,/679:<=>?ACDEFGINTX]^_`abcdefghijlmnot)c(G - B =dHV7"q""###--%..(/s/o333B7q777758m88899 :\BBB CLCwCDE0EFMFFF+GaGGGHeHHHHHIMXXXXXXXXXXXXXXXXXXXXXXXtXXX  "$@apwy}!t!!t!!8@(  t  s *? 3"?b  3 #" `? b  3 #" `? \  # #" `? V  # "? \  3 "? B S  ?$2M0*rt"Atif 7t7STT1 _Hlt268697440 _Hlt268697441 _Hlt270597009 _Hlt270597010 _Hlt270597134 _Hlt270597135 _Hlt268698442 _Hlt268697504 _Hlt268697505 _Hlt207529534 _Hlt207529535 _Hlt268695031 _Hlt268695032 _Hlt165948116 _Hlt165948117 _Hlt207525725 _Hlt165947259 _Hlt165947260 _Hlt268695109 _Hlt268695110 _Hlt265504096 _Hlt78191409 _Hlt78191441 _Hlt109711007 _Hlt109711008 _Hlt267557320 _Hlt267557321 _Hlt110760429 _Hlt110760430 _Hlt113861767 _Hlt267557856 _Hlt143397068 _Hlt143397069 _Hlt143397041 _Hlt143397042 _Hlt105922003 _Hlt105922004 _Hlt105478568 _Hlt105478569 _Hlt105901147 _Hlt105901148 _Hlt105478576 _Hlt105478577 _Hlt105478612 _Hlt105478613 _Hlt105901133 _Hlt105901134 _Hlt78109543 _Hlt143397019KK LL""""""""####333377VFVFHHHHHHHHHHHHHHHHM@@@@@@@@@ @ @ @ @ @@@@@@@@@@@@@@@@@@@ @!@"@#@$@%@&@'@(@)@*@+@,@-@.@/@0@LL MM""""""""####333377WFWFHHHHHHHHHHHHHHHHM7~w7~nx7~nx7~*urn:schemas-microsoft-com:office:smarttags PersonName9*urn:schemas-microsoft-com:office:smarttagsStateB *urn:schemas-microsoft-com:office:smarttagscountry-region x M:RTWZ[\_FFNFFLLLLLLLLLLLLLLLLLLMMMMM&M'MeMmMMGI34L:RTWX_++D#DDDFFNFFFF-J2JILKLLLLLLLLLLLLLmMnMM3333333*c) ( CcnMWYdp[$mIpIuIIIJLnLLLLLLLLLLLLLLLL'MeMmMnMrMtM|M~MMMMMMMLLLLLLLLLLLLLmMM-e6J=4F?D ڈg rNk \TQJ$8&_mYh|  *6;R fnzo]ڈe#J%'}U,%~#D2]2 !wq3으n4r`F.;@&k&> ww>liCP8oCXL6CNNzSڈj UtȺ$JV$7WY ~!RZNJBcJD,-3d4 dLOg:hڈ9Ejb61kP.1GmTv_VpfM~]p6JT2qpjr`&RuPHzz}rNh^`OJPJQJ^Jo(-h^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHhhh^h`CJOJQJaJo(hHoh88^8`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hH   ^ `OJQJo( ^`OJQJo(o   ^ `OJQJo(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo(hvv^v`CJOJQJaJo(hHohFF^F`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHoh^`OJQJo(hHhVV^V`OJQJo(hHh&&^&`OJQJ^Jo(hHoh^`OJQJo(hHh^`CJOJQJaJo(hHoh  ^ `OJQJ^Jo(hHoh  ^ `OJQJo(hHhxx^x`OJQJo(hHhHH^H`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhhh^h`CJOJQJaJo(hHoh88^8`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`CJOJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh ^`OJQJo(h pp^p`OJQJo(oh @ @ ^@ `OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h PP^P`OJQJo(oh   ^ `OJQJo(   ^ `OJQJo( ^`OJQJo(o   ^ `OJQJo(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo(h^`CJ OJQJo(lh ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(h hh^h`OJQJo(h 88^8`OJQJo(oh ^`OJQJo(h   ^ `OJQJo(h   ^ `OJQJo(oh xx^x`OJQJo(h HH^H`OJQJo(h ^`OJQJo(oh ^`OJQJo(   ^ `OJQJo( ^`OJQJo(o   ^ `OJQJo(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo(h^`CJOJQJaJo(hHoh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh ^`OJQJo(h pp^p`OJQJo(oh @ @ ^@ `OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h PP^P`OJQJo(oh   ^ `OJQJo(h^`CJOJQJaJo(hHhFF^F`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHoh^`OJQJo(hHhVV^V`OJQJo(hHh&&^&`OJQJ^Jo(hHoh^`OJQJo(hH^`CJOJQJo(hHpp^p`OJQJ^Jo(hHo@ @ ^@ `OJQJo(hH^`OJQJo(hH^`OJQJ^Jo(hHo^`OJQJo(hH^`OJQJo(hHPP^P`OJQJ^Jo(hHo  ^ `OJQJo(hHh p@ ^h `p56CJOJQJo( ^`OJQJo(opp^`p56CJOJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(   ^ `OJQJo( ^`OJQJo(o   ^ `OJQJo(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo( ^`hH. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.^`o()   ^ `OJQJo( ^`OJQJo(o   ^ `OJQJo(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo(h^`CJOJQJaJo(hHoh^`CJOJQJaJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH   ^ `OJQJo( ^`OJQJo(o   ^ `OJQJo(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo(hhh^h`CJOJQJaJo(hHoh88^8`CJOJQJaJo(hHo L^`LhH.   ^ `hH.   ^ `hH. xLx^x`LhH. HH^H`hH. ^`hH. L^`LhH.h^`CJOJQJaJo(hHoh^`CJOJQJaJo(hHo pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.   ^ `OJQJo( ^`OJQJo(o   ^ `OJQJo(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo( hh^h`hH.h88^8`CJOJQJaJo(hHo L^`LhH.   ^ `hH.   ^ `hH. xLx^x`LhH. HH^H`hH. ^`hH. L^`LhH.h ^`OJQJo(h pp^p`OJQJo(oh @ @ ^@ `OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h PP^P`OJQJo(oh   ^ `OJQJo(h ^`OJQJo(h pp^p`OJQJo(oh @ @ ^@ `OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h PP^P`OJQJo(oh   ^ `OJQJo(h ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(h hh^h`OJQJo(h 88^8`OJQJo(oh ^`OJQJo(h   ^ `OJQJo(h   ^ `OJQJo(oh xx^x`OJQJo(h HH^H`OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`56o(.h pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(^`o(()^`OJPJQJ^J() pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`CJOJQJaJo(hHhFF^F`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHoh^`OJQJo(hHhVV^V`OJQJo(hHh&&^&`OJQJ^Jo(hHoh^`OJQJo(hH   ^ `OJQJo( ^`OJQJo(o   ^ `OJQJo(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo(h hh^h`OJQJo(h88^8`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHohxx^x`OJQJo(hHhHH^H`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh ^`OJQJo(hpp^p`CJ OJQJo(lh @ @ ^@ `OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h PP^P`OJQJo(oh   ^ `OJQJo(   ^ `OJQJo( ^`OJQJo(o   ^ `OJQJo(   ^ `OJQJo( xx^x`OJQJo(o HH^H`OJQJo( ^`OJQJo( ^`OJQJo(o ^`OJQJo(h hh^h`OJQJo(h 88^8`OJQJo(oh ^`OJQJo(h   ^ `OJQJo(h   ^ `OJQJo(oh xx^x`OJQJo(h HH^H`OJQJo(h ^`OJQJo(oh ^`OJQJo(h^`OJPJQJ^Jo(-h^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHhvv^v`CJOJQJaJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh\ \ ^\ `OJQJ^Jo(hHoh,,^,`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh ^`OJQJo(h pp^p`OJQJo(oh @ @ ^@ `OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h PP^P`OJQJo(oh   ^ `OJQJo(hh^h`o(.88^8`.L^`L.  ^ `.  ^ `.xLx^x`L.HH^H`.^`.L^`L.hvv^v`CJOJQJaJo(hHohFF^F`OJQJ^Jo(hHoh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJ^Jo(hHoh^`OJQJo(hHhVV^V`OJQJo(hHh&&^&`OJQJ^Jo(hHoh^`OJQJo(hH-k&>-3d_VpBcRu fU,$JV7WY1kjr!RZ| ;:hn4wq3zSoC/?D Gm/o]w>/iC d=j UF.;XLCNe#9Eje~]p_mYQJ$k zz}g #D2OOgT2qO']2--                                v                 h        kh                                           v        Y1         Z       h        h        x.       h                                                                   Ҵ2       :       h                  kh       h                  +:                 V(                bS0BD @ [x y . q  "|lV+?is`-N? g|!f%+&f'2u',-g.t0Us1g345 64@U&B+C+C$DF1VK{LQ)N PaAPRVS _T}T&XjXM(ZNZD_KarhviijF k:l;qllfnFq]q,srtUHuvFy!yz4z{,>|m|03~#?~A~EJDQeq4 jH}7g_ef r}U0S({LB}Ybv_d5D p3:l#SFnDIJvB"a|A[g 6`6BU?GLbzgnpHgNlCc`drZ"bsg& 8,_.OLL@`~``4LM`@``8@`@UnknownDLazorikDLazorik20070717T14264586FDLazorik G* Times New Roman5Symbol3. * ArialQTimes New Roman Bold5. *aTahoma7.  VerdanaI. ??Arial Unicode MS?= * Courier New;WingdingsA BCambria Math" h&&m 'A'm 'A'! 4dmLmL 2q HP ?A2! xx MEMORANDUM Susan Lettamy-                           ! " # $ % & ' ( ) * + , Oh+'0  8 D P \hpx MEMORANDUM Susan Lett Normal.dotmamy2Microsoft Office Word@F#@OE@zY@zYm 'A՜.+,D՜.+,` px  Department of Public Health'mL  MEMORANDUM Title 8@ _PID_HLINKSAL9hKhttp://www.mass.gov/dph/flu*:!Hhttp://www.immunize.org/vis*$E-http://www.immunize.org/fda/pa_influenza.asp*B6http://www.cdc.gov/mmwr/preview/mmwrhtml/00047135.htm*R ?6http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5502a1.htm* <-http://www.cdc.gov/mmwr/pdf/rr/rr59e0729.pdf*92http://www.cdc.gov/vaccines/recs/acip/default.htm*]6&http://www.cdc.gov/flu/professionals/*UB36http://www.cdc.gov/flu/professionals/infectioncontrol*~?0?http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html*~?-?http://www.cdc.gov/hicpac/2007IP/2007isolationPrecautions.html*89* http://www.mass.gov/handwashing*UB'6http://www.cdc.gov/flu/professionals/infectioncontrol*}$Khttp://www.mass.gov/Eeohhs2/docs/dph/disease_reporting/guide/influenza.rtf*t*!Hhttp://www.mass.gov/Eeohhs2/docs/dph/cdc/reporting/rdiq_reg_summary.rtf*w1http://flu.masspro.org/*ei+http://www.cms.hhs.gov/AdultImmunizations/*nx8https://www.gskvaccinesdirect.com/gsk/en/US/adirect/gsk*J]-https://www.novartisvaccinesdirect.com/index**&https://www.vaccineshoppe.com/*<l'http://www.preventinfluenza.org/ivats/*`a 3http://www.massmed.org/AM/Template.cfm?Section=Flu*C^ ]http://www.mass.gov/Eeohhs2/docs/dph/quality/hcq_circular_letters/ltc_facilities_0611468.pdf*`=Ohttp://www.mass.gov/Eeohhs2/docs/dph/cdc/immunization/record_vaccine_admin.pdf*n [http://www.mass.gov/Eeohhs2/docs/dph/quality/hcq_circular_letters/flu_all_attachment_b.pdf*88Whttp://www.cms.hhs.gov/NursingHomeQualityInits/downloads/NHQIVaccinationSupplement.pdf*  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuwxyz{|}~      "#$%&'(*+,-./016Root Entry FY8Data vx1Table)WordDocumentSummaryInformation(!DocumentSummaryInformation8)CompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q